Contact
searchSearch
HMP Global
Login

Desmoid Tumors Specialty Channel

Desmoid Tumors
Specialty Channel
News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Desmoid Tumors
04/28/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial...
04/28/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology

News

News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Desmoid Tumors
04/28/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial...
04/28/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology

Interactive Features

Recent News

News
Varegacestat Advances Toward FDA Review in Desmoid Tumors
04/30/2026
Stephanie Holland
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase 3 RINGSIDE trial, a New Drug Application for varegacestat has been submitted to the FDA for the treatment of adult patients with desmoid tumors.
Based on results from the phase...
04/30/2026
Oncology
News
Nirogacestat Improves Outcomes Across Prognostic Subgroups of Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis of the phase 3 DeFi trial demonstrate that nirogacestat provides consistent clinical benefit across prognostic subgroups of patients with desmoid tumors.
Results from a post hoc analysis...
04/30/2026
Oncology
News
FOG-001 Shows Early Activity in Patients With Desmoid Tumors
04/30/2026
Stephanie Holland
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study demonstrate that FOG-001 shows early clinical activity with manageable safety in patients with desmoid tumors.
Results from a phase 1/2 study...
04/30/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Desmoid Tumors
04/28/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improves progression-free survival compared with placebo in advanced or refractory desmoid tumors.
Results from a phase 3 trial...
04/28/2026
Oncology
News
Pegylated Liposomal Doxorubicin Significantly Extends Progression-Free Survival in Advanced Desmoid Tumors
01/13/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors.
Results from a phase 3 trial...
01/13/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
FDA Alerts
Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer
05/07/2026
Stephanie Holland
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the...
05/07/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology
News
Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the...
05/07/2026
Oncology
News
ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology
FDA Approval
FDA Approves Vepdegestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
05/01/2026
Emily Estrada
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase 3 VERITAC-2 trial, the FDA has approved vepdegestrant for patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Based on results from the phase...
05/01/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use